Top

BY Laura Sussman

Matching targeted therapies to tumor-specific gene mutations across tumor types improved survival in patients with advanced cancer, compared to those receiving non-matched, standard-of-care treatment, MD Anderson trial data revealed.

Long-term data from the center’s IMPACT trial, which compares treatments based on molecular profiling to standard-of-care treatments, showed the three-year, overall survival rate was 15 percent in...

Apostolia Tsimberidou, M.D., Ph.D.

BY Laura Sussman

In recent years, five new immunotherapy drugs have been approved to treat patients diagnosed with urinary cancer. But the drugs, which held...

BY Laura Sussman

In a small Phase II study of early-stage breast cancer patients with BRCA 1 and 2 mutations, researchers found that more than half of women...

BY Laura Sussman

In a randomized, Phase II trial led by researchers at MD Anderson, adding the PARP inhibitor veliparib to a standard chemotherapy agent improved overall response rates (ORR) in patients with small cell lung cancer (SCLC). Researchers also identified a select group of patients — those whose tumors expressed SLFN11 — who also saw a progression-free survival (PFS) and overall survival (OS) benefit, suggesting a promising biomarker for the...

lung cancer metastasis

BY Laura Sussman

For patients with advanced, inoperable stage 3 lung cancer, chemotherapy and a specialized form of radiation treatment known as proton...

BY Laura Sussman

High response rates to a pair of combination therapies point to potentially new options for a group of metastatic melanoma patients who have...

BY Laura Sussman

An advanced form of image-guided radiation therapy known as intensity modulated proton therapy (IMPT) has shown early promise for the treatment...

BY Laura Sussman

A new study from MD Anderson finds that women with early-stage breast cancer who had an intermediate risk recurrence score (RS)...

BY Laura Sussman

For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma (LGSC), hormone maintenance...

BY Laura Sussman

Breast cancer patients with dense breast tissue have almost a two-fold increased risk of developing disease in the other breast, according...